{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.4","upperLimit":"79.9","value":"65.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Percentage of participants with a best overall response of CR or PR, or stable disease (SD) which lasts for 24 weeks or longer.\n\nCR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.\n\nPR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically.\n\nSD: Partient did not qualify for CR, PR, or progressive disease and has stable nonenhancing (T2/FLAIR) lesions on same or lower doses of corticosteroids compared with baseline scan and clinically stable status.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)","id":"OG000","title":"HGG Cohort: Dabrafenib and Trametinib"}],"paramType":"NUMBER","populationDescription":"All participants on the HGG cohort to whom study treatment had been assigned and who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approx. 4.8 years","title":"HGG Cohort: Clinical Benefit Rate (CBR) as Per Central Independent Assessment Using RANO Criteria","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}